Literature DB >> 11053811

Lung cancer following previous extrapulmonary malignancy.

G Massard1, X Ducrocq, M Beaufigeau, S Elia, R Kessler, J Hervé, J Wihlm.   

Abstract

OBJECTIVE: Having demonstrated a poor prognosis of operable lung cancer in patients with previous head and neck malignancies, we intended to evaluate prognosis of lung cancer in patients with a history of extrapulmonary and extracervical malignancies.
METHODS: The population of this study included 55 patients; these were 40 males and 15 females, with a mean age 64.4+/-8.6 years. The previous malignancy was considered tobacco-induced in 15 patients (kidney, two; bladder, ten; esophagus, three), hormone-dependant in 18 (breast, six; female genital, eight; prostate, four), and miscellaneous in 22 (leukemia, four; skin, seven; colon, 11). Following complete resection, 25 patients were classified stage I, 13 were stage II, and 17 were stage IIIA.
RESULTS: There were two early perioperative deaths (3.6%), and three during the second month owing to cardiovascular complications. At the conclusion of the study (July 1st, 1997), 32 further patients had died (58.2%): 25 had progression of lung cancer, one had progression of previous malignancy, and six were without evidence of disease. Five-year survival (Kaplan-Meier) was estimated 47+/-10.2% in stage I (median 44 months), 30.8+/-15.6% in stage II (median 26 months), and 16. 7+/-9.9% in stage IIIA (median 17 months). When excluding five early perioperative deaths, 5-year survival was 51.1+/-10.6% in stage I (median 93 months), 33.3+/-16.7% in stage II (median 36.5 months), and 19.0+/-11.2% in stage IIIA (median 20.5 months). Comparing the three groups defined according to location of previous malignancy, there was no significant difference neither in stage distribution (chi(2)=1.326; P=0.857), nor in 5-year survival estimates: 38.9+/-12. 9% (median 27 months) after tobacco-induced malignancies, 38.9+/-11. 5% (median 24 months) following hormone-dependant malignancies, and 28.4+/-10.2% (median 28 months) following miscellaneous cancers (chi(2)=0.059; P=0.9707).
CONCLUSIONS: In opposition to data collected in patients with previous head and neck cancer, survival estimates according to stage were contained within the universally accepted range no high risk group has been identified. Resection of lung cancer with curative intent is a fair option in patients with previous extrapulmonary malignancy.

Entities:  

Mesh:

Year:  2000        PMID: 11053811     DOI: 10.1016/s1010-7940(00)00571-6

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  9 in total

1.  Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis.

Authors:  Andrew L Laccetti; Sandi L Pruitt; Lei Xuan; Ethan A Halm; David E Gerber
Journal:  Lung Cancer       Date:  2016-05-31       Impact factor: 5.705

2.  Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.

Authors:  Andrew L Laccetti; Sandi L Pruitt; Lei Xuan; Ethan A Halm; David E Gerber
Journal:  J Natl Cancer Inst       Date:  2015-02-09       Impact factor: 13.506

3.  Impact of prior cancer on eligibility for lung cancer clinical trials.

Authors:  David E Gerber; Andrew L Laccetti; Lei Xuan; Ethan A Halm; Sandi L Pruitt
Journal:  J Natl Cancer Inst       Date:  2014-09-24       Impact factor: 13.506

4.  Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practice.

Authors:  Martin Faehling; Birgit Schwenk; Sebastian Kramberg; Sabine Fallscheer; Matthias Leschke; Jörn Sträter; Robert Eckert
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-30       Impact factor: 4.553

5.  Predictors of primary lung cancer in a solitary pulmonary lesion after a previous malignancy.

Authors:  Akie Nakadate; Masashi Nakadate; Yasunori Sato; Tassei Nakagawa; Katsuya Yoshida; Yoshio Suzuki; Yukihiro Yoshida
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-09-08

6.  Patients with a Previous History of Malignancy Undergoing Lung Cancer Screening: Clinical Characteristics and Radiologic Findings.

Authors:  Darragh F Halpenny; Jane D Cunningham; Niamh M Long; Ramon E Sosa; Michelle S Ginsberg
Journal:  J Thorac Oncol       Date:  2016-05-17       Impact factor: 15.609

7.  Second primary lung carcinoma in patients with first primary breast carcinoma: two case reports and review of the literature.

Authors:  Shi-Ping Luh; Ching-Chung Chiang; Mao-Te Chuang
Journal:  Cases J       Date:  2009-07-24

8.  Survival analysis of patients with primary breast duct carcinoma and lung adenocarcinoma: a population-based study from SEER.

Authors:  Fengyuan Lv; Mingliang Cheng; Liang Jiang; Xiaoping Zhao
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379

9.  Dual Primary Cancer Patients With Lung Cancer as a Second Primary Malignancy: A Population-Based Study.

Authors:  Congkuan Song; Donghu Yu; Yujin Wang; Qingwen Wang; Zixin Guo; Jingyu Huang; Sheng Li; Weidong Hu
Journal:  Front Oncol       Date:  2020-10-26       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.